Dr Reddy's Laboratories, an integrated global pharmaceutical company announced to market 'DiaResQ', a product of PanTheryx, Inc., a global medical nutrition company through a multi-country supply and licensing agreement.

The company said, "The agreement grants Dr. Reddy's the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ, for infectious diarrhea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and selected Latin America markets."

"The company will market the product in India and Nepal under the 'Reliqua' brand," it added.

DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function.

Mark A. Braman, President and CEO of PanTheryx said, "The opportunity to work with Dr. Reddy's to broadly introduce DiaResQ represents a significant milestone for our company."

Dr. Reddy's Co-chairman and CEO, GV Prasad said, “This innovative product will address a significant unmet need in the area of diarrhea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr. Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve."

According to World Health Organization, infectious diarrhea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five.

Shares of the company declined Rs 63.05, or 1.56%, to trade at Rs 3,975.00. The total volume of shares traded was 20,358 at the BSE (3.30 p.m., Thursday).